Article

Glandular lesions of the urinary bladder: clinical significance and differential diagnosis

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Histopathology (Impact Factor: 3.3). 05/2011; 58(6):811-34. DOI: 10.1111/j.1365-2559.2010.03651.x
Source: PubMed

ABSTRACT Williamson S R, Lopez-Beltran A, Montironi R & Cheng L (2011) Histopathology 58, 811–834 Glandular lesions of the urinary bladder: clinical significance and differential diagnosis
A variety of glandular or pseudoglandular lesions may be seen in the urinary bladder, ranging from those that are entirely benign to aggressive-behaving malignant primary and secondary tumours. Lesions with minimal to no evident premalignant potential include several proliferative and reactive processes, such as cystitis cystica and cystitis glandularis, although the possibility exists for confusion of such lesions with an infiltrative neoplasm, particularly in limited biopsy specimens. Similarly, ectopic tissues of Müllerian origin may be seen occasionally in the urinary bladder and their differentiation from a true glandular neoplasm is important to avoid improper treatment. As urothelial carcinoma has a propensity for divergent differentiation, a wide spectrum of morphological variants exists with varying degrees of glandular differentiation. Some such variants have demonstrated clinical behaviour that is more aggressive than their histology would suggest, thus deserving recognition and potentially different treatment. In this paper, we review the glandular lesions of the urinary bladder ranging from benign proliferative processes to malignant primary and secondary neoplasms, with emphasis on clinical significance and features useful in resolving their differential diagnoses.

0 Followers
 · 
138 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mit der aktuell gültigen WHO-Klassifikation der Harnblasenkarzinome von 2004 wurden sowohl nicht-invasive als auch invasive Neoplasien anhand der Zellmorphologie und den zugrunde liegenden genetischen Veränderungen hinsichtlich prognostisch relevanter Gruppen neu kategorisiert. Obwohl weite Teile der Klassifikation unverändert blieben, führten in den letzten Jahren kleine wesentliche Änderungen jedoch häufig zu Unsicherheiten und primärer Skepsis gegenüber den Neuerungen bei Urologen und Pathologen. Der vorliegende Artikel bietet eine Übersicht über die aktuelle WHO-Klassifikation mit Schwerpunkt auf Herausforderungen in der uropathologischen Diagnostik, mit denen sich die Uropathologen, und daher auch die behandelnden Urologen, auseinandersetzen müssen. Diese Herausforderungen umfassen u. a. uneindeutige Befunde, schwierige Differentialdiagnosen und seltenere Differenzierungen mit entsprechenden Formulierungen/Ausdrücken im pathologischen Befund sowie deren Bedeutung bzw. Auswirkung für die Praxis (weitere Abklärung, Prognose, Therapie).
    Der Urologe 07/2013; 52(7). DOI:10.1007/s00120-013-3225-2 · 0.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The vast majority of urachal epithelial neoplasms are adenocarcinomas with several described morphologic subtypes that include both enteric and nonenteric histologies. Adenocarcinoma from several other primaries may mimic any of these urachal adenocarcinoma subtypes in the bladder or at distant sites. However, data regarding the immunohistochemical profile of urachal carcinoma are limited, let alone its correlation with the different histologic subtypes that may have implications in the differential diagnostic workup with their morphologic mimics. Herein, we performed an immunohistochemical analysis in a broad spectrum of 39 urachal epithelial neoplasms (34 adenocarcinomas, 1 urothelial carcinoma, and 4 noninvasive mucinous cystic tumors), 13 urachal remnants, and 6 secondary colonic adenocarcinomas of the bladder, using an antibody panel that included novel and traditional gastrointestinal tract-associated markers. Expression levels of p63, CK7, CK20, CDX2, nuclear β-catenin, claudin-18, and Reg IV in urachal adenocarcinoma were as follows: 3%, 50%, 100%, 85%, 6%, 53%, and 85%. In urachal adenocarcinoma subtypes, expression levels of CDX2, nuclear β-catenin, claudin-18, and Reg IV were as follows: mucinous (8/8, 0/8, 6/8, 8/8), enteric (10/11, 1/11, 3/11, 8/11), not otherwise specified (5/7, 0/7, 3/7, 5/7), and signet ring cell (4/6, 0/6, 4/6, 6/6) type. All urachal adenocarcinomas had membrano-cytoplasmic β-catenin staining and only 2 tumors had nuclear localization that were focal to moderate, in contrast to secondary colonic adenocarcinoma of the bladder, which mostly had both membrano-cytoplasmic and nuclear positivity. Claudin-18 positivity was observed only in frankly malignant tumors and not in noninvasive urachal tumors and urachal remnants. Reg IV expression seemed to be related to mucin production, which was often diffuse in mucinous and signet ring cell subtypes and focal in enteric subtype, with goblet cell-like reactivity similar to secondary colonic adenocarcinoma. p63 expression was present in urothelial urachal remnants (3/3) and contrasted with CDX2 expression seen in glandular (5/6) and mixed urothelial/glandular remnants (2/4). Thus, this study showed that CDX2 is expressed by urachal remnants of glandular type, noninvasive urachal mucinous cystic tumors and urachal adenocarcinomas, and can be diffuse in urachal adenocarcinomas, even without the classic enteric morphology. Nuclear localization of β-catenin can rarely occur in urachal adenocarcinoma; however, diffuse nuclear reactivity argues against its diagnosis. The novel gastrointestinal tract markers claudin-18 and Reg IV are both expressed in urachal adenocarcinoma, including in signet ring cell carcinoma, and thus refutes the suggested specificity for gastrointestinal tract signet ring cell carcinomas. An immunohistochemical panel that includes β-catenin and CK7 may have value in differentiating urachal adenocarcinoma of enteric morphology from colonic adenocarcinoma. Overall, this study suggests that the different morphologic presentations of urachal adenocarcinomas have a relatively similar or overlapping immunophenotype. Knowledge of the similarity in immunostaining to its different morphologic mimics may help avoid misdiagnosis in urachal adenocarcinoma.
    The American journal of surgical pathology 06/2011; 35(6):787-98. DOI:10.1097/PAS.0b013e3182189c11 · 4.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIMS: To investigate relative telomere length in inverted urothelial neoplasms, including inverted papilloma and urothelial carcinoma with an inverted growth pattern. Telomere shortening has been implicated as an early event in the development of epithelial malignancies in a number of organ systems. METHODS AND RESULTS: Formalin-fixed, paraffin-embedded tissue sections from 77 cases were studied, including 26 cases of inverted papilloma, 26 urothelial carcinomas with inverted growth, and 25 cases of cystitis glandularis. Quantitative fluorescence in-situ hybridization (FISH) was performed on interphase nuclei, utilizing a telomere-specific peptide nucleic acid probe to assess telomeric signal intensity. Relative telomere lengths for urothelial carcinoma with inverted growth, cystitis glandularis and inverted papilloma were 29%, 84%, and 91%, respectively. A statistically significant reduction in relative telomere length was present between urothelial carcinoma with inverted growth and inverted papilloma (P < 0.001); no significant difference was detected between normal urothelium, cystitis glandularis, and inverted papilloma. CONCLUSIONS: Significant telomere shortening in urothelial carcinoma with inverted growth as compared with inverted papilloma distinguishes the two lesions, and supports the notion that inverted papilloma is a benign neoplasm with a distinct pathogenetic mechanism of development. Telomeric FISH analysis may be a useful biomarker in distinguishing inverted papilloma from urothelial carcinoma with inverted growth.
    Histopathology 09/2012; 62(4). DOI:10.1111/his.12030 · 3.30 Impact Factor
Show more